Moderiba Alternatives Compared
| Moderiba | Mavyret | Vosevi |
|
|---|
| Moderiba (ribavirin) | Mavyret (glecaprevir / pibrentasvir) | Vosevi (sofosbuvir / velpatasvir / voxilaprevir) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hepatitis C. Moderiba may also be used for purposes not listed in this medication guide. |
Prescription only
Mavyret is an antiviral combination agent that is approved to treat all six genotypes (1-6) of hepatitis C virus (HCV) in adults and children aged 12 years of age and older. It is one of the most... View more |
Prescription only
Vosevi is a stand-alone combination antiviral treatment that may be used to treat HCV infection of genotypes 1 through 6 in adults who have been previously treated with certain other antiviral... View more |
Related suggestions Hepatitis C
|
|||||||||||||||
| More about Moderiba (ribavirin) | More about Mavyret (glecaprevir / pibrentasvir) | More about Vosevi (sofosbuvir / velpatasvir / voxilaprevir) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Moderiba has an average rating of 8.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Mavyret has an average rating of 8.4 out of 10 from a total of 422 ratings on Drugs.com. 79% of reviewers reported a positive effect, while 8% reported a negative effect. |
Vosevi has an average rating of 10.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
| Lower cost generic approved | ||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Mavyret prices |
View all Vosevi prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other ribavirin brands include: Rebetol, RibaTab, Virazole |
N/A |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
960 hours |
13 hours |
33 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 18 drugs are known to interact with Moderiba:
|
A total of 194 drugs are known to interact with Mavyret:
|
A total of 227 drugs are known to interact with Vosevi:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
August 03, 2017 |
N/A |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.